

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



Elongin A1 (R129) Peptide

Cat No.: BS2530P

Background

Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors including renal carcinoma, hemangio-blastoma of the central nervous system and pheochromocytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex. The VHL protein migrates with an apparent molecular weight of 38 kDa. The Elongin A subunit is 773 amino acids in length and has an apparent molecular weight of 110 kDa, while Elongin B and C are 18 kDa and 15 kDa proteins, respectively.

Swiss-Prot

Q14241

Applications

Blocking

Specificity

This peptide can be used with studies using BS2530 Elongin A1 (R129) pAb.

Purification & Purity

Synthetic peptide Elongin A1 (R129). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.